Digital Molecular Risk Assessment Transplant Market

Digital molecular risk assessment transplant sales will expand through 2036, with next-generation sequencing (NGS) at 31.0% within the technology segment, kidney transplant at 30.3% of the transplant type category and pre-transplant risk assessment at 38.3% of application demand in 2026. The market is projected to record a 16.3% CAGR between 2026 and 2036.